Table 1.
Characteristics of brain tumor survivors
| N | % | |
|---|---|---|
| Age at diagnosis | ||
| < 5 years | 22 | (28.2) |
| 5–9 years | 26 | (33.3) |
| 10–14 years | 21 | (26.9) |
| 15–20 years | 9 | (11.5) |
| Time since diagnosis | ||
| 5–9 years | 12 | (15.4) |
| 10–14 years | 30 | (38.5) |
| 15–19 years | 22 | (28.2) |
| 20+ years | 14 | (17.9) |
| Tumor type | ||
| Astrocytic | 40 | (51.3) |
| Medulloblastoma/Ependymoma | 22 | (28.2) |
| Other | 16 | (20.5) |
| Primary tumor location | ||
| Cerebrum | 11 | (14.1) |
| Thalamus | 5 | (6.4) |
| Sellar/parasellar/hypothalamic | 18 | (23.1) |
| Pineal | 4 | (5.1) |
| Brainstem | 8 | (10.3) |
| Brainstem and spine | 2 | (2.6) |
| Cerebellum | 25 | (32.1) |
| Optic nerve | 5 | (6.4) |
| Extent of surgery | ||
| None | 10 | (12.8) |
| Biopsy | 8 | (10.3) |
| Partial resection | 11 | (14.1) |
| Near total resection | 13 | (16.7) |
| Gross total resection | 36 | (46.2) |
| Chemotherapy | ||
| Any | 24 | (30.8) |
| Specific chemotherapy agents | ||
| Vincristine | 19 | (79.2) |
| Cisplatin | 15 | (62.5) |
| Carboplatin | 7 | (29.2) |
| Radiation | ||
| None | 26 | (33.3) |
| Cranial | 52 | (66.7) |
| Cranial and spinal | 23 | (29.5) |
| Median | Range | |
|---|---|---|
| Cranial doses (cGy) | 5400 | 3600–7020 |
| Site specific radiation doses | ||
| Spine | 3600 | 2430–6050 |
| Posterior fossa | 5070 | 0–7020 |
| Temporal lobe | 5040 | 0–7200 |
| Frontal cortex | 3520 | 0–6000 |
| Occipital/parietal lobe | 3520 | 0–7020 |